Pharmaceuticals
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
2459
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...
2024-12-04 18:10
4769
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...
2024-12-04 13:09
2779
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...
2024-12-04 00:00
2922
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...
2024-12-03 21:00
2186
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...
2024-12-03 20:00
2592
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...
2024-12-03 18:47
2586
MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research
* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...
2024-12-02 11:16
2390
BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech
CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...
2024-11-29 23:58
6674
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...
2024-11-29 22:00
5619
Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...
2024-11-29 20:31
4962
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...
2024-11-29 10:23
2599
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...
2024-11-28 11:58
3285
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...
2024-11-27 14:00
2907
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...
2024-11-26 22:00
3186
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have...
2024-11-26 08:44
2802
Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and deve...
2024-11-26 08:30
2578
ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder
BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a therapy f...
2024-11-26 01:00
3113
Cistto Launches the "Humanized Anti-Aging Global Scientist Alliance" in China, Empowering Products with Cutting-Edge Science
LOS ANGELES, Nov. 25, 2024 /PRNewswire/ -- As an emerging brand specializing in sensitive skin repair, Cistto is grounded in skin science and committed to advancing skin health through the latest dermatological breakthroughs and cutting-edge biotechnology. Cistto is steadfast in its promise to de...
2024-11-25 23:00
2591
Food Allergy: LongBio's LP-003 achieves its fourth IND approval
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA,China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-IgE antibody, to begin a clinical trial for the treatment ...
2024-11-25 22:00
3391
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 277 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
11421
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
10617
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8856
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
8389
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
8138